For many older Americans struggling with obesity, Medicare’s new GLP-1 weight-loss coverage sounded like long-awaited relief. Drugs like Wegovy and Zepbound have dominated headlines because of their ability to help patients lose significant amounts of weight while improving conditions tied to diabetes and heart disease.
Beginning in July 2026, Medicare’s temporary GLP-1 Bridge program is expected to offer qualifying beneficiaries access to certain weight-loss medications for around $50 per month. However, healthcare experts say many seniors are about to discover that getting approved may be much harder than the headlines suggest. Here is what you need to know before you get your hopes up.
